Product Details:

CasNo： 141922-90-9

Molecular Formula： C17H21Cl2N3O3

Appearance： White to off-white Powder

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

Azasetron Hydrochloride 

CAS：123040‑16‑4 Code：Y‑25130；

Brand name：SEROTONE®（日本）

Drug class：Potent, selective 5‑HT₃ (serotonin‑3) receptor antagonist, antiemetic

Molecular Weight：386.27

First approval：Japan 1994；Available as injectable and oral tablet dosage forms

✅ Official Indication

Azasetron hydrochloride is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic cancer chemotherapy (e.g. cisplatin‑containing regimens) in adult patients. It is also used for postoperative nausea and vomiting (PONV) in some clinical settings.

Administration: Intravenous injection or oral tablet; typically dosed 10 mg prior to chemotherapy, effect sustains approximately 24 hours。

📄 Detailed Product English Description

Azasetron hydrochloride (Y‑25130) is a potent, highly‑selective competitive antagonist of serotonin 5‑HT₃ receptors. Chemically it belongs to benzamide derivative class, structurally distinct from indole‑based 5‑HT₃ antagonists such as ondansetron and granisetron. Chemotherapeutic agents trigger serotonin release from gastrointestinal enterochromaffin cells. Released serotonin activates 5‑HT₃ receptors located on vagal afferent nerve terminals in the gut and on chemoreceptor trigger zone within the brainstem, initiating emetic reflex signals. Azasetron competitively blocks these peripheral and central 5‑HT₃ receptors, interrupting the afferent vomiting signal pathway, thereby suppressing chemotherapy‑evoked nausea and both acute and delayed‑phase vomiting episodes. It exhibits minimal affinity toward other neurotransmitter receptors. The API is white‑to‑off‑white crystalline powder, soluble in water. The marketed finished products are intravenous injection and oral tablets. Clinical administration is given before chemotherapy; its anti‑emetic duration can last up to around 24 hours. It is widely adopted for managing CINV (chemotherapy‑induced nausea and vomiting) in oncology practice.

⚠️ Safety brief note

Common adverse reactions include headache, dizziness, dry mouth, constipation and abdominal discomfort. Contraindicated in patients with hypersensitivity to azasetron or other 5‑HT₃ antagonists, and patients with gastrointestinal obstruction. Protect from light, as the substance is prone to photodegradation.